Fiche publication
Date publication
septembre 2007
Auteurs
Membres identifiés du Cancéropôle Est :
Dr COUDERT Bruno
,
Pr FUMOLEAU Pierre
,
Dr FAVIER Laure
Tous les auteurs :
Fumoleau P, Campone M, Coudert B, Mayer F, Favier L, Ferrant E
Lien Pubmed
Résumé
Because of the involvement of the receptors of the ErbB family in breast oncogenesis, numerous approaches aimed at targeting these receptors have been developed. A monoclonal anihody directed against the ErbB2 (HER2) receptor, trastuzumab (Herceptin 0), has shown a high activity in palliative, neo-adjuvant and, more recently, in adjuvant setting, and has been considered as bringing a "therapeutic revolution" in breast oncology. Other antibodies, directed against ErbB2 or EGFR, are being evaluated, especially lapatinib, which should be marketed in the next future. Combinations between targeted therapies and cytotoxic chemotherapy will certainly allow to take the greatest benefits from these new treatment approaches. triangle.
Référence
Bull Cancer. 2007;94(7 Suppl):F147-70.
